| Abstract |
Objective To analyze the effects of quetiapine on psychobehavioral symptoms (BPSD), cognitive function and neurotransmitters in patients with Alzheimers disease (AD). Methods 90 patients with AD treated in our hospital from January 2020 to December 2022 were included in the study and divided into the experimental group and the control group, 45 cases in each group, using random number table method. The control group was treated with Memantine hydrochloride , and the experimental group was treated with quetiapine on the basis of Memantine hydrochloride. Both groups were treated for 3 months. The effects after 3 months of treatment, BPSD, cognitive function, quality of life, electrocardiogram and neurotransmitters before and after 3 months of treatment, and the occurrence of adverse reactions during treatment were compared between the two groups. Results After 3 months of treatment, the total response rate was higher in the experimental group (84.44% vs 62.22%, P<0.05). After 3 months of treatment, scores of behavioral pathology in Alzheimers disease rating scale (BEHAVE-AD), brief psychiatric rating scale (BPRS) and neuropsychiatric questionnaire (NPI), Alzheimer disease assessment scale (ADAS-cog) score and activity of daily living scale (ADL) of the two groups all decreased, and were lower among the experimental groups (P<0.05). Compared with before treatment, there was no significant difference in electrocardiogram indexes between the two groups after 3 months of treatment (P>0.05). Compared with before treatment, after 3 months of treatment, the scores of mini-mental state examination (MMSE) and serum levels of norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) in the two groups increased, and those in the experimental group were higher (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (15.56% vs 20.00%, P>0.05). Conclusion Quetiapine combined with Memantine hydrochloride could control the BPSD of patients with AD, promote the recovery of cognitive function and improve the quality of life, which might be related to the regulation levels of neurotransmitter, the effect was exact, and the addition of drugs did not increase the changes of electrocardiogram indicators, and the safety was good.
|